US › Healthcare

Oric Pharmaceuticals Inc (ORIC)

US · Healthcare · Biotechnology

$13.47+27.08%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-35.8M
Profit YoY
-19.1%
EPS
$-0.34
EPS estimate
$-0.32

EPS came in at -0.34 against a street estimate of -0.32 — a miss of 6.3%.

Key statistics

Market cap
$1.17B
Forward P/E
0.0
P/B
2.97
Book value
$4.02
EPS (TTM)
$-1.31
52-week high
$14.93
52-week low
$7.23
50-day MA
$9.52
200-day MA
$10.60
Beta
1.01

Analyst view

Analysts rate Oric Pharmaceuticals Inc a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $20.69.

Shareholding

Insiders
5.85%
Institutions
114.19%

Largest institutional holders

FundStake
Nextech Invest, Ltd.6.92%
EcoR1 Capital, LLC6.50%
BlackRock Inc5.78%
Viking Global Investors LP5.63%
T. Rowe Price Associates, Inc.5.20%
Pfizer Inc4.62%
Vanguard Group Inc4.39%
SR ONE CAPITAL MANAGEMENT, LP4.36%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Oric Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.